FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328105024> ?p ?o ?g. }

• W4328105024 endingPage "106427" @default.
• W4328105024 startingPage "106427" @default.
• W4328105024 abstract "Prostate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimulating factor-1/colony stimulating factor-1 receptor (CSF-1/CSF-1R) signaling pathway plays a crucial role in the polarization of the immunosuppressive TAMs, M2 macrophages. Downregulation of CSF-1R is known to reprogram the immunosuppressive TAMs, M2 macrophages, to the immunostimulatory phenotype, M1 macrophages. Sialic acid is a ligand for Siglec-1 (CD169) which is overexpressed on M2 macrophages with little expression in other phenotypes. Therefore, a sialic acid-targeted cyclodextrin-based nanoparticle was developed to specifically deliver CSF-1R siRNA to M2 macrophages. The nanoparticles were studied in vitro using both human and mouse prostate cancer cell lines. Results show that the targeted nanoparticles achieved cell specific delivery to M2 macrophages via the sialic acid-CD169 axis. The expression of CSF-1R was significantly downregulated in M2 macrophages (29.64% for targeted vs 19.31% for non-targeted nanoparticles in THP-1-derived M2 macrophages and 38.94% for targeted vs 18.51% for non-targeted nanoparticles in RAW 264.7-derived M2 macrophages, n = 4, p < 0.01). The resulting reprograming of M2 macrophages to M1 enhanced the level of apoptosis in the prostate cancer cells in a Transwell model (49.17% for targeted vs 37.68% for non-targeted nanoparticles in PC-3 cells and 69.15% for targeted vs 44.73% for non-targeted nanoparticles in TRAMP C1 cells, n = 3, p < 0.01). Thus, this targeted cyclodextrin-based siRNA drug delivery system provides a potential strategy for prostate cancer immunotherapy." @default.
• W4328105024 created "2023-03-22" @default.
• W4328105024 creator A5037097258 @default.
• W4328105024 creator A5037138504 @default.
• W4328105024 creator A5040262462 @default.
• W4328105024 creator A5078087258 @default.
• W4328105024 creator A5081976284 @default.
• W4328105024 date "2023-06-01" @default.
• W4328105024 modified "2023-10-18" @default.
• W4328105024 title "Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer" @default.
• W4328105024 cites W1611419331 @default.
• W4328105024 cites W1969286776 @default.
• W4328105024 cites W1970914111 @default.
• W4328105024 cites W1978486312 @default.
• W4328105024 cites W2007838251 @default.
• W4328105024 cites W2033737641 @default.
• W4328105024 cites W2034085314 @default.
• W4328105024 cites W2064441112 @default.
• W4328105024 cites W2076743146 @default.
• W4328105024 cites W2092817859 @default.
• W4328105024 cites W2114570899 @default.
• W4328105024 cites W2466093998 @default.
• W4328105024 cites W2585743330 @default.
• W4328105024 cites W2622646269 @default.
• W4328105024 cites W2751194532 @default.
• W4328105024 cites W2755912463 @default.
• W4328105024 cites W2890796276 @default.
• W4328105024 cites W2898415660 @default.
• W4328105024 cites W2908288105 @default.
• W4328105024 cites W2912325761 @default.
• W4328105024 cites W2921622709 @default.
• W4328105024 cites W2981273060 @default.
• W4328105024 cites W3005264007 @default.
• W4328105024 cites W3008479555 @default.
• W4328105024 cites W3013253749 @default.
• W4328105024 cites W3026714337 @default.
• W4328105024 cites W3042650007 @default.
• W4328105024 cites W3044837108 @default.
• W4328105024 cites W3087550005 @default.
• W4328105024 cites W3146533240 @default.
• W4328105024 cites W3146716199 @default.
• W4328105024 cites W3162577508 @default.
• W4328105024 cites W3171808984 @default.
• W4328105024 cites W3174442355 @default.
• W4328105024 cites W3176528055 @default.
• W4328105024 cites W3177350416 @default.
• W4328105024 cites W3181071111 @default.
• W4328105024 cites W3193200952 @default.
• W4328105024 cites W4206841660 @default.
• W4328105024 cites W4212921252 @default.
• W4328105024 cites W4213062434 @default.
• W4328105024 cites W4234220341 @default.
• W4328105024 cites W642285930 @default.
• W4328105024 doi "https://doi.org/10.1016/j.ejps.2023.106427" @default.
• W4328105024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36948408" @default.
• W4328105024 hasPublicationYear "2023" @default.
• W4328105024 type Work @default.
• W4328105024 citedByCount "6" @default.
• W4328105024 countsByYear W43281050242023 @default.
• W4328105024 crossrefType "journal-article" @default.
• W4328105024 hasAuthorship W4328105024A5037097258 @default.
• W4328105024 hasAuthorship W4328105024A5037138504 @default.
• W4328105024 hasAuthorship W4328105024A5040262462 @default.
• W4328105024 hasAuthorship W4328105024A5078087258 @default.
• W4328105024 hasAuthorship W4328105024A5081976284 @default.
• W4328105024 hasBestOaLocation W43281050241 @default.
• W4328105024 hasConcept C104317684 @default.
• W4328105024 hasConcept C121608353 @default.
• W4328105024 hasConcept C126322002 @default.
• W4328105024 hasConcept C166703698 @default.
• W4328105024 hasConcept C185592680 @default.
• W4328105024 hasConcept C202751555 @default.
• W4328105024 hasConcept C203014093 @default.
• W4328105024 hasConcept C22615655 @default.
• W4328105024 hasConcept C2776107976 @default.
• W4328105024 hasConcept C2776682551 @default.
• W4328105024 hasConcept C2777701055 @default.
• W4328105024 hasConcept C2779244956 @default.
• W4328105024 hasConcept C2780115458 @default.
• W4328105024 hasConcept C2780192828 @default.
• W4328105024 hasConcept C3020616263 @default.
• W4328105024 hasConcept C502942594 @default.
• W4328105024 hasConcept C54009773 @default.
• W4328105024 hasConcept C54355233 @default.
• W4328105024 hasConcept C55493867 @default.
• W4328105024 hasConcept C67705224 @default.
• W4328105024 hasConcept C71924100 @default.
• W4328105024 hasConcept C81885089 @default.
• W4328105024 hasConcept C86803240 @default.
• W4328105024 hasConcept C8891405 @default.
• W4328105024 hasConcept C96232424 @default.
• W4328105024 hasConceptScore W4328105024C104317684 @default.
• W4328105024 hasConceptScore W4328105024C121608353 @default.
• W4328105024 hasConceptScore W4328105024C126322002 @default.
• W4328105024 hasConceptScore W4328105024C166703698 @default.
• W4328105024 hasConceptScore W4328105024C185592680 @default.
• W4328105024 hasConceptScore W4328105024C202751555 @default.
• W4328105024 hasConceptScore W4328105024C203014093 @default.

• next